Intabio Raises $9.5 Million in Series A Financing
Funding Will Drive Commercial Development and Launch of Blaze™ Analytical System
NEWARK, Calif., Oct. 30, 2018 /PRNewswire/ -- Intabio, Inc. today announced the close of a $9.5 million Series A financing round led by Northpond Ventures, a science-driven venture capital ﬁrm headquartered in Bethesda, Maryland. Launched in 2016, Intabio raised $3.2M in its initial Series Seed financing in 2017. Intabio's previous investors including Genoa Ventures and Vertical Venture Partners also participated.
Intabio's Blaze™ platform performs a comprehensive analysis of antibody and protein biopharmaceutical products in development with blazing speed, offering 100-fold higher throughput over traditional methods. The Blaze system helps biopharma companies meet the accelerated timelines required for breakthrough therapy applications, reducing the risk of costly production delays and failures.
"Northpond is delighted to join Intabio, as the Blaze platform has the potential to make a powerful impact on the key biomanufacturing performance drivers – improving product quality, reducing manufacturing cost, and increasing speed to market." said Michael P. Rubin, M.D., Ph.D., Founder and CEO at Northpond. Dr. Rubin joins Intabio's board of directors alongside Intabio's Series Seed lead investor, Dr. Jenny Rooke of Genoa Ventures.
"Our Early Access customers are providing valuable insights into the vastly improved workflows provided by the Blaze system, both as a stand-alone QC or MS-integrated system for comprehensive characterization," added Intabio's CEO and co-founder, Lena Wu, Ph.D. "These Series A funds fuel our commercial system development and our pursuit of a portfolio of analytical tools for biotherapeutic product quality characterization."
Intabio, Inc. is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing. Intabio's first product, the Blaze system, is a microchip-based instrument system that will provide rapid detection and identification of subtle protein modifications - modifications that can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins. For more information, please visit us at www.intabio.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/intabio-raises-9-5-million-in-series-a-financing-300739340.html
SOURCE Intabio, Inc.